Fine-tuning licensing strategies to boost MSC-based immunomodulatory secretome.

ABSTRACT:

Background

Immune-mediated inflammatory diseases (IMIDs) are a major global health challenge, affecting millions of people and often lacking effective treatments. The mesenchymal stromal cell (MSC)-derived secretome has emerged as a promising therapeutic approach owing to its potent immunomodulatory properties. However, progress has been hindered by the lack of standardized protocols for inducing a robust immunomodulatory MSC phenotype.

Methods

In this study, we focused on optimizing the MSC-derived secretome to enhance its ability to suppress activated immune cells. Specifically, we examined (1) the effects of IFN-γ and TNF-α, individually and in combination, to uncover potential synergy; (2) the ideal cytokine ratio and (3) concentration; (4) the best production time for t

SUBMITTER: Rossello-Gelabert M 

PROVIDER: S-EPMC12004826 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature